Alpelisib (BYL719) vs Inavolisib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: PI3K-alpha · full HR+/HER2- Metastatic Breast Cancer pipeline

Alpelisib (BYL719)

Marketed by Novartis

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule (PI3K-alpha inhibitor)
Reliable signal

NCT02437318 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled trial with 572 participants. The primary clinical endpoint, investigator-assessed progression-free survival in the PIK3CA-mutant cohort, was met: median progression-free survival was 11.0 versus 5.7 months, with a hazard ratio of 0.65 and one-sided p=0.00065.

Next expected readout: December 2026 · NCT05563220 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36) (met)

Result source: NCT02437318

Inavolisib · Itovebi

Marketed by Roche

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT04191499 · Phase 2/3 · active, not recruiting

Participants were randomly assigned 1:1 and both participants and investigators were masked, with a placebo plus palbociclib and fulvestrant comparator and 325 participants. The primary endpoint, progression-free survival, favored inavolisib with a hazard ratio of 0.43 (95% CI 0.32 to 0.59, p<0.0001), so it was met.

Next expected readout: December 2026 · NCT03006172 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (Up to 3.7 years): Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3) (met)

Result source: NCT04191499

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlpelisib (BYL719)Inavolisib
PFS, median11 vs 5.7+5.3 vs placebon 169NCT02437318
7 other results
15 vs 7.3+7.7 vs placebon 161NCT04191499
OS, median39.3 vs 31.4+7.9 vs placebon 169NCT02437318
4 other results
—Trial running · NCT04191499
ORR26.6% vs 13.4%+13.2 vs placebon 169NCT02437318
4 other results
—Trial running · NCT04191499
Clinical benefit rate61.5% vs 44.8%+16.7 vs placebon 169NCT02437318
4 other results
—Trial running · NCT04191499

PFS, median

Alpelisib (BYL719)
11 vs 5.7+5.3 vs placebon 169NCT02437318
7 other results
Inavolisib
15 vs 7.3+7.7 vs placebon 161NCT04191499

OS, median

Alpelisib (BYL719)
39.3 vs 31.4+7.9 vs placebon 169NCT02437318
4 other results
Inavolisib
—Trial running · NCT04191499

ORR

Alpelisib (BYL719)
26.6% vs 13.4%+13.2 vs placebon 169NCT02437318
4 other results
Inavolisib
—Trial running · NCT04191499

Clinical benefit rate

Alpelisib (BYL719)
61.5% vs 44.8%+16.7 vs placebon 169NCT02437318
4 other results
Inavolisib
—Trial running · NCT04191499
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alpelisib (BYL719): 4 of 4 rows · Inavolisib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlpelisib (BYL719)Inavolisib
Dropout rate
n/a: no completion milestonea
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 25 more results
47.5%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
99.2%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
100%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
92.1%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2: Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
14.3%Cohort 3:Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
—350 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%250 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%BYL-719 (Alpelisib) Dose Expansion
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
33.3%300mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
9.1%250mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3
Discontinued due to AEs
4.9%a
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 25 more results
10%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
15.7%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
11.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.3%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2: Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
—Cohort 3:Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
—350 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—250 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—BYL-719 (Alpelisib) Dose Expansion
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—300mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
—250mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
0.6%
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3
Serious AEs
38.7%a
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 25 more results
25%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30.2%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2: Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 3:Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
0%350 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%300 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%250 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%BYL-719 (Alpelisib) Dose Expansion
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
25%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
57.1%DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
50%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
33.3%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
16.7%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
28.6%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
50%300mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
27.3%250mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
24.1%
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3
Most frequent reported AEs
a
hyperglycaemia 64.1% (placebo 9.4%)
diarrhoea 58.8% (placebo 16.7%)
nausea 46.8% (placebo 22.3%)
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 22 more results
hyperglycaemia 90%
stomatitis 37.5%
diarrhoea 35%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 64.6%
hyperglycaemia 59.8%
nausea 46.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
asthenia 100%
blood creatinine increased 100%
diarrhoea 100%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 68.3%
hyperglycaemia 64.3%
nausea 54%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 67.5%
diarrhoea 54%
nausea 40.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70%
hyperglycaemia 60%
fatigue 50%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
aspartate aminotransferase increased 50%
breast pain 50%
cpk increased 50%
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
fatigue 71.4%
headache 42.9%
nausea 42.9%
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
350 mg BYL-719/Alpelisib
hyperglycemia 100%
diarrhea 85.7%
electrolyte imbalance 71.4%
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BYL-719/Alpelisib
diarrhea 100%
electrolyte imbalance 100%
fatigue 100%
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
250 mg BYL-719/Alpelisib
anemia 100%
nausea 100%
diarrhea 66.7%
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
nausea 66.7%
diarrhea 63.3%
hyperglycemia 63.3%
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
rash maculo-papular 33.3%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
rash maculo-papular 50%
abdominal pain 25%
alkaline phosphatase increased 25%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
aspartate aminotransferase increased 28.6%
abdominal pain 14.3%
blood bilirubin increased 14.3%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
rash maculo-papular 33.3%
confusion 16.7%
lymphocyte count decreased 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
lymphocyte count decreased 33.3%
rash maculo-papular 33.3%
anemia 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
abdominal pain 0%
alanine aminotransferase increased 0%
alkaline phosphatase increased 0%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
aspartate aminotransferase increased 33.3%
rash maculo-papular 33.3%
alkaline phosphatase increased 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
lymphocyte count decreased 42.9%
neutrophil count decreased 42.9%
white blood cell decreased 42.9%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
300mg BYL719, 3.6mg/kg T-DM1
aspartate aminotransferase increased 83.3%
fatigue 83.3%
hypoalbuminemia 83.3%
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
250mg BYL719, 3.6mg/kg T-DM1
aspartate aminotransferase increased 90.9%
hyperglycemia 81.8%
peripheral sensory neuropathy 81.8%
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
neutropenia 54.3% (placebo 54.9%)
hyperglycaemia 53.7% (placebo 7.4%)
diarrhoea 48.1% (placebo 16%)
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3

Notes

  1. aPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alpelisib (BYL719)

Overall Survival 39.3 vs 31.4 placebo months
time to event · months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
37.29 vs 34.3 placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 26.6% (n=169) vs 13.4% (n=172) placebo
responder rate · % of participants
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
20.9% (n=115) vs 13.4% (n=172) placebo
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 61.5% (n=169) vs 44.8% (n=172) placebo
responder rate · % of participants
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
53.9% (n=115) vs 44.8% (n=172) placebo
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Time to ECOG-PS Deterioration 34.07 vs NA placebo months
time to event · months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
NA vs NA placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Time to GHS/QoL Deterioration 18.14 vs 19.98 placebo months
time to event · months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
7.39 vs 19.98 placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
EORTC QLQ-C30 GHS -2.477 vs -0.369 placebo score @ 8wk
absolute change · score
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 17 more results
1.524 vs -0.369 placebo score @ 8wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-1.796 vs -2.685 placebo score @ 16wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
2.866 vs -2.685 placebo score @ 16wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-3.01 vs -0.337 placebo score @ 24wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1.383 vs -0.337 placebo score @ 24wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.802 vs -0.891 placebo score @ 32wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1.063 vs -0.891 placebo score @ 32wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.815 vs -1.854 placebo score @ 40wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
13.232 vs -1.854 placebo score @ 40wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-3.635 vs -1.46 placebo score @ 48wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-1.617 vs 0.248 placebo score @ 56wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-1.937 vs -1.979 placebo score @ 64wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.525 vs -1.526 placebo score @ 72wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-1.135 vs -1.495 placebo score @ 84wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-3.869 vs -3.581 placebo score @ 96wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.158 vs -2.068 placebo score @ 108wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.928 vs -2.593 placebo score @ 120wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS 6mo 53.8% (n=119) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
46.5% (n=114) @ 26wk
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
53% (n=115) @ 26wk
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
PFS 8 months
time to event · months
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
5.6 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
5.6 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
PFS2 15.2 months
time to event · months
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
13 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
13.5 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
ORR 19.3% (n=119)
responder rate · % of participants
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
17.5% (n=114)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
25.2% (n=115)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
Clinical Benefit 46.2% (n=119)
responder rate · % of participants
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
35.1% (n=114)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.3% (n=115)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 13.8 months
time to event · months
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
6.5 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
16.5 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination

+ 6 further endpoints in the CSV export.

Breast Cancer

Shared mechanism: PI3K-alpha · full Breast Cancer pipeline

Alpelisib (BYL719)

Marketed by Novartis

Approved in Breast Cancersmall molecule (PI3K-alpha inhibitor)
Reliable signal

NCT02437318 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled trial with 572 participants. The primary clinical endpoint, investigator-assessed progression-free survival in the PIK3CA-mutant cohort, was met: median progression-free survival was 11.0 versus 5.7 months, with a hazard ratio of 0.65 and one-sided p=0.00065.

Next expected readout: December 2026 · NCT05563220 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36) (met)

Result source: NCT02437318

Inavolisib · Itovebi

Marketed by Roche

Approved in Breast Cancersmall molecule
Reliable signal

NCT04191499 · Phase 2/3 · active, not recruiting

Participants were randomly assigned 1:1 and both participants and investigators were masked, with a placebo plus palbociclib and fulvestrant comparator and 325 participants. The primary endpoint, progression-free survival, favored inavolisib with a hazard ratio of 0.43 (95% CI 0.32 to 0.59, p<0.0001), so it was met.

Next expected readout: December 2026 · NCT07245797 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (Up to 3.7 years): Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3) (met)

Result source: NCT04191499

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Alpelisib (BYL719): 5 of 5 rows · Inavolisib: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlpelisib (BYL719)Inavolisib
PFS
time to event · months
11 vs 5.7 placebo monthsa,b,c,d
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 4 more doses
10.97 vs 5.65 placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
10.9 vs 3.7 placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.43 vs 7.23 placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9 vs 3.7 placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
15 vs 7.3 placebo monthsb,c,d
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3
Dropout rate
n/a: no completion milestonee
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 26 more results
47.5%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
99.2%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
100%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
92.1%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2: Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
14.3%Cohort 3:Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
28.2%
NCT01923168 · Phase 2 · registry result, not featured evidence · combination
—350 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%250 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%BYL-719 (Alpelisib) Dose Expansion
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
33.3%300mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
9.1%250mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3
Discontinued due to AEs
4.9%e
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 26 more results
10%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
15.7%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
11.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.3%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2: Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
—Cohort 3:Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
9.2%
NCT01923168 · Phase 2 · registry result, not featured evidence · combination
—350 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—250 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—BYL-719 (Alpelisib) Dose Expansion
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
—300mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
—250mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
0.6%
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3
Serious AEs
38.7%e
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 26 more results
25%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30.2%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2: Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 3:Zotatifin in Combination
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
16.2%
NCT01923168 · Phase 2 · registry result, not featured evidence · combination
0%350 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%300 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%250 mg BYL-719/Alpelisib
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%BYL-719 (Alpelisib) Dose Expansion
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
0%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
25%DOSE FINDING PHASE, Arm A, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
57.1%DOSE FINDING PHASE, Arm B, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
50%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
33.3%Dose Finding Phase, Arm C, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
0%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
16.7%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
28.6%Dose Finding Phase, Arm D, Cohort
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
50%300mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
27.3%250mg BYL719, 3.6mg/kg T-DM1
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
24.1%
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3
Most frequent reported AEs
e
hyperglycaemia 64.1% (placebo 9.4%)
diarrhoea 58.8% (placebo 16.7%)
nausea 46.8% (placebo 22.3%)
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
hyperglycaemia 90%
stomatitis 37.5%
diarrhoea 35%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 64.6%
hyperglycaemia 59.8%
nausea 46.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
asthenia 100%
blood creatinine increased 100%
diarrhoea 100%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 68.3%
hyperglycaemia 64.3%
nausea 54%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 67.5%
diarrhoea 54%
nausea 40.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70%
hyperglycaemia 60%
fatigue 50%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
aspartate aminotransferase increased 50%
breast pain 50%
cpk increased 50%
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
fatigue 71.4%
headache 42.9%
nausea 42.9%
NCT05101564 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 53.1% (placebo 6.4%)
diarrhoea 50.8% (placebo 15.2%)
rash 44.6% (placebo 8%)
NCT01923168 · Phase 2 · registry result, not featured evidence · combination
350 mg BYL-719/Alpelisib
hyperglycemia 100%
diarrhea 85.7%
electrolyte imbalance 71.4%
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BYL-719/Alpelisib
diarrhea 100%
electrolyte imbalance 100%
fatigue 100%
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
250 mg BYL-719/Alpelisib
anemia 100%
nausea 100%
diarrhea 66.7%
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
nausea 66.7%
diarrhea 63.3%
hyperglycemia 63.3%
NCT02379247 · Phase 1/2 · registry result, not featured evidence · combination
rash maculo-papular 33.3%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
rash maculo-papular 50%
abdominal pain 25%
alkaline phosphatase increased 25%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
aspartate aminotransferase increased 28.6%
abdominal pain 14.3%
blood bilirubin increased 14.3%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
rash maculo-papular 33.3%
confusion 16.7%
lymphocyte count decreased 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
lymphocyte count decreased 33.3%
rash maculo-papular 33.3%
anemia 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
abdominal pain 0%
alanine aminotransferase increased 0%
alkaline phosphatase increased 0%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
aspartate aminotransferase increased 33.3%
rash maculo-papular 33.3%
alkaline phosphatase increased 16.7%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
lymphocyte count decreased 42.9%
neutrophil count decreased 42.9%
white blood cell decreased 42.9%
NCT01870505 · Phase 1 · registry result, not featured evidence · combination
300mg BYL719, 3.6mg/kg T-DM1
aspartate aminotransferase increased 83.3%
fatigue 83.3%
hypoalbuminemia 83.3%
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
250mg BYL719, 3.6mg/kg T-DM1
aspartate aminotransferase increased 90.9%
hyperglycemia 81.8%
peripheral sensory neuropathy 81.8%
NCT02038010 · Phase 1 · registry result, not featured evidence · combination
neutropenia 54.3% (placebo 54.9%)
hyperglycaemia 53.7% (placebo 7.4%)
diarrhoea 48.1% (placebo 16%)
NCT04191499 · Phase 2/3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 2/3

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2/3 versus Phase 3.
  3. cPopulation context differs: prior_therapy differs (naive versus experienced).
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation comparability has not been reviewed for 26 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alpelisib (BYL719)

Overall Survival 39.3 vs 31.4 placebo months
time to event · months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
37.29 vs 34.3 placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 26.6% (n=169) vs 13.4% (n=172) placebo
responder rate · % of participants
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
20.9% (n=115) vs 13.4% (n=172) placebo
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
43.3% (n=60) vs 44.8% (n=67) placebo @ 24wk
NCT01923168 · Phase 2 · registry result, not featured evidence · combination
63.4% (n=71) vs 61% (n=59) placebo @ 24wk
NCT01923168 · Phase 2 · registry result, not featured evidence · combination
Clinical Benefit 61.5% (n=169) vs 44.8% (n=172) placebo
responder rate · % of participants
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
53.9% (n=115) vs 44.8% (n=172) placebo
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Time to ECOG-PS Deterioration 34.07 vs NA placebo months
time to event · months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
NA vs NA placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Time to GHS/QoL Deterioration 18.14 vs 19.98 placebo months
time to event · months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
7.39 vs 19.98 placebo months
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
EORTC QLQ-C30 GHS -2.477 vs -0.369 placebo score @ 8wk
absolute change · score
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 17 more results
1.524 vs -0.369 placebo score @ 8wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-1.796 vs -2.685 placebo score @ 16wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
2.866 vs -2.685 placebo score @ 16wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-3.01 vs -0.337 placebo score @ 24wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1.383 vs -0.337 placebo score @ 24wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.802 vs -0.891 placebo score @ 32wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1.063 vs -0.891 placebo score @ 32wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.815 vs -1.854 placebo score @ 40wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
13.232 vs -1.854 placebo score @ 40wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-3.635 vs -1.46 placebo score @ 48wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-1.617 vs 0.248 placebo score @ 56wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-1.937 vs -1.979 placebo score @ 64wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.525 vs -1.526 placebo score @ 72wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-1.135 vs -1.495 placebo score @ 84wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-3.869 vs -3.581 placebo score @ 96wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.158 vs -2.068 placebo score @ 108wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
-2.928 vs -2.593 placebo score @ 120wk
NCT02437318 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS 6mo 53.8% (n=119) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
46.5% (n=114) @ 26wk
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
53% (n=115) @ 26wk
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
PFS 8 months
time to event · months
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
5.6 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
5.6 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
PFS2 15.2 months
time to event · months
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
13 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
13.5 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
ORR 19.3% (n=119)
responder rate · % of participants
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
17.5% (n=114)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
25.2% (n=115)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
Clinical Benefit 46.2% (n=119)
responder rate · % of participants
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
35.1% (n=114)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.3% (n=115)
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 13.8 months
time to event · months
No placebo or comparator arm
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
6.5 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
16.5 months
NCT03056755 · Phase 2 · registry result, not featured evidence · combination

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alpelisib (BYL719)'s landscape · Inavolisib's landscape